ASLAN Pharmaceuticals (ASLN) News Today → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free ASLN Stock Alerts $0.40 -0.01 (-2.42%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Eventglobenewswire.com - May 7 at 7:30 AMASLAN Pharmaceuticals (NASDAQ:ASLN) Stock Rating Reaffirmed by HC Wainwrightamericanbankingnews.com - May 5 at 6:54 AMASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologicsglobenewswire.com - May 2 at 9:00 AMASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumabglobenewswire.com - April 30 at 7:00 AMASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conferencefinance.yahoo.com - April 24 at 9:53 AMAslan Announces Positive Results For Phase 2 Study Of Eblasakimab In AD Patientsmarkets.businessinsider.com - April 22 at 2:54 PMASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patientsglobenewswire.com - April 22 at 8:45 AMASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Announces Receipt of Nasdaq Noticefinanznachrichten.de - April 20 at 8:35 AMASLAN Pharmaceuticals Announces Receipt of Nasdaq Noticeglobenewswire.com - April 19 at 5:10 PMASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - April 14 at 12:04 AMASLAN Falls On Q4 Figuresmsn.com - April 12 at 7:52 PMASLN Stock Earnings: ASLAN Pharma Misses EPS for Q4 2023markets.businessinsider.com - April 12 at 2:51 PMASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - April 12 at 8:00 AMAslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disordersglobenewswire.com - March 27 at 8:07 AMAnalysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Urogen Pharma (URGN) and Legend Biotech (LEGN)markets.businessinsider.com - March 18 at 12:36 PMASLN Apr 2024 5.000 callfinance.yahoo.com - March 18 at 7:35 AMWeek In Review: Under Pressure From U.S. Congress, WuXi AppTec Resigns From BIOseekingalpha.com - March 17 at 4:59 AMSmart Home Healthcare Market to Reach USD 160.7 Billion by 2032, at 24.3% CAGR: Astute Analyticafinance.yahoo.com - March 14 at 8:50 PMREGN May 2024 885.000 callfinance.yahoo.com - March 14 at 3:49 PMASLAN Pharmaceuticals announces $5M registered direct offeringmsn.com - March 12 at 8:31 PMmarketbeat.com - March 12 at 2:39 PMASLAN Pharmaceuticals Announces $5 Million Registered Direct Offeringglobenewswire.com - March 12 at 2:34 PMPiper 'confident' partner or buyer will see benefit of Aslan's eblasakimabrealmoney.thestreet.com - March 12 at 10:30 AMU.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.12%msn.com - March 11 at 6:47 PMmarketbeat.com - March 11 at 3:24 PMmarketbeat.com - March 11 at 3:17 PMmarketbeat.com - March 11 at 3:11 PMmarketbeat.com - March 11 at 2:55 PMmarketbeat.com - March 11 at 2:49 PMmarketbeat.com - March 11 at 2:43 PMBank Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Monday Tradingmsn.com - March 11 at 1:46 PMASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisorsfinance.yahoo.com - March 6 at 6:22 PMAsian Equities Traded in US as ADRs Edge Higher Monday Afternoonmsn.com - March 4 at 6:18 PMTech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Thursday Tradingmsn.com - February 29 at 11:27 AMASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstatglobenewswire.com - February 29 at 7:00 AMBank, Auto Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Wednesdaymsn.com - February 28 at 12:55 PMAsian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Tradingmsn.com - February 27 at 10:51 AMASLAN Pharmaceuticals Limited (ASLN)finance.yahoo.com - February 20 at 8:30 PMASLAN Pharmaceuticals Ltd ADRmorningstar.com - February 20 at 3:29 PMAslan Pharmaceuticals Ltd. ADRwsj.com - February 17 at 8:19 AMTechnology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Modestly Higher in Thursday Tradingmsn.com - December 14 at 12:40 PMASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programsfinanznachrichten.de - December 12 at 10:25 AMASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programsfinance.yahoo.com - December 12 at 10:25 AMAsian Equities Traded in the US as American Depositary Receipts Open Week Sharply Lower in Monday Tradingmsn.com - December 4 at 12:43 PMASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conferencefinance.yahoo.com - November 20 at 9:59 AMASLAN Pharmaceuticals Ltd ADR ASLNmorningstar.com - November 4 at 9:53 AMASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summitfinance.yahoo.com - November 3 at 7:17 AMPiper Sandler Reaffirms Their Buy Rating on Aslan Pharmaceuticals (ASLN)markets.businessinsider.com - October 31 at 11:46 PMAslan Pharmaceuticals: Promising Financial Results and Optimistic Drug Trial Outcomes Boost Buy Ratingmarkets.businessinsider.com - October 31 at 11:46 PMASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitisfinance.yahoo.com - October 24 at 12:09 PM Get ASLAN Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon Musk Secret Crypto Plot Exposed (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. ASLN Media Mentions By Week ASLN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASLN News Sentiment▼0.000.36▲Average Medical News Sentiment ASLN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASLN Articles This Week▼41▲ASLN Articles Average Week Get ASLAN Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: HEPA News TENX News CANF News TRVN News VCNX News CMMB News KTTA News CYCN News ADXS News BNOX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASLN) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDems have chosen Biden replacement?Paradigm Press348 million Americans lives to END as we know it?The Oxford ClubGold Set to EXPLODE!Gold Safe ExchangeHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ASLAN Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.